Lysosomal Therapeutics Lands $4,800,000 Seed Funding

  • Feed Type
  • Date
    5/13/2014
  • Company Name
    Lysosomal Therapeutics
  • Mailing Address
    19 Blackstone Street Cambridge, MA 02139 USA
  • Company Description
    LTI’s unique approach to discovering new drugs for neurodegenerative diseases is based on research performed in the lab of Dr. Dimitri Krainc, one of the company’s founders, at Massachusetts General Hospital (MGH), a founding member of Partners HealthCare and an affiliate of Harvard Medical School.
  • Website
    http://www.lysosomaltx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $4,800,000
  • Transaction Round
    Seed
  • Proceeds Purposes
    This seed funding will be instrumental in enabling LTI to progress its GCase program through the lead-generation process and in setting us up for preclinical development.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy